于2024年，公司于西藏分别占锌精矿总产量的11.1%、铅精矿总产量的4.2%及铜精矿总产量的0.1%。西 藏的铅精矿及铜精矿生产由龙头公司主导。于2024年，位于西藏的两大公司分别占铅精矿生产总市场份 额的36.1%及31.6%；均设于西藏当地的两大公司亦于西藏分别占铜精矿生产总市场份额的44.2%及 42.3%。 公开资料显示，智汇矿业是一家矿业公司，专注集团在中国西藏的锌、铅及铜探矿、采矿、精矿生产及 销售业务。根据上海有色网的资料，以2024年西藏锌精矿、铅精矿及铜精矿的平均年产量计，集团分别 排名第五位、第四位及第五位。 智通财经APP获悉，智汇矿业(02546)首挂上市，公告显示，每股定价4.51港元，共发行1.21952亿股股 份，每手1000股，所得款项净额约4.951亿港元。截至发稿，涨139.47%，报10.8港元，成交额1.5亿港 元。 ...

智汇矿业(02546)首挂上市，公告显示，每股定价4.51港元，共发行1.21952亿股股份，每手1000股，所 得款项净额约4.951亿港元。截至发稿，涨139.47%，报10.8港元，成交额1.5亿港元。 公开资料显示，智汇矿业是一家矿业公司，专注集团在中国西藏的锌、铅及铜探矿、采矿、精矿生产及 销售业务。根据上海有色网的资料，以2024年西藏锌精矿、铅精矿及铜精矿的平均年产量计，集团分别 排名第五位、第四位及第五位。 于2024年，公司于西藏分别占锌精矿总产量的11.1%、铅精矿总产量的4.2%及铜精矿总产量的0.1%。西 藏的铅精矿及铜精矿生产由龙头公司主导。于2024年，位于西藏的两大公司分别占铅精矿生产总市场份 额的36.1%及31.6%；均设于西藏当地的两大公司亦于西藏分别占铜精矿生产总市场份额的44.2%及 42.3%。 ...

智汇矿业港股上市首日高开近140%，报10.8港元/股。 来源：滚动播报 ...

客户端 智汇矿业（02546）首挂上市，公告显示，每股定价4.51港元，共发行1.21952亿股股份，每手1000股， 所得款项净额约4.951亿港元。截至发稿，股价上涨139.47%，现报10.8港元，成交额1.5亿港元。 公开资料显示，智汇矿业是一家矿业公司，专注集团在中国西藏的锌、铅及铜探矿、采矿、精矿生产及 销售业务。根据上海有色网的资料，以2024年西藏锌精矿、铅精矿及铜精矿的平均年产量计，集团分别 排名第五位、第四位及第五位。 于2024年，公司于西藏分别占锌精矿总产量的11.1%、铅精矿总产量的4.2%及铜精矿总产量的0.1%。西 藏的铅精矿及铜精矿生产由龙头公司主导。于2024年，位于西藏的两大公司分别占铅精矿生产总市场份 额的36.1%及31.6%；均设于西藏当地的两大公司亦于西藏分别占铜精矿生产总市场份额的44.2%及 42.3%。 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 责任编辑：卢昱君 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 公开资料显示，智汇矿业是一家矿业公司，专注集团在中国西藏的锌、铅及铜探矿、采矿、精矿生产及 销售业务。根据上海有色网的 ...

公开资料显示，智汇矿业是一家矿业公司，专注集团在中国西藏的锌、铅及铜探矿、采矿、精矿生产及 销售业务。根据上海有色网的资料，以2024年西藏锌精矿、铅精矿及铜精矿的平均年产量计，集团分别 排名第五位、第四位及第五位。 智通财经APP获悉，智汇矿业(02546)首挂上市，公告显示，每股定价4.51港元，共发行1.21952亿股股 份，每手1000股，所得款项净额约4.951亿港元。截至发稿，涨139.47%，报10.8港元，成交额1.5亿港 元。 于2024年，公司于西藏分别占锌精矿总产量的11.1%、铅精矿总产量的4.2%及铜精矿总产量的0.1%。西 藏的铅精矿及铜精矿生产由龙头公司主导。于2024年，位于西藏的两大公司分别占铅精矿生产总市场份 额的36.1%及31.6%；均设于西藏当地的两大公司亦于西藏分别占铜精矿生产总市场份额的44.2%及 42.3%。 ...

智汇矿业公布配发结果，全球发售1.22亿股H股，其中香港公开发售占10%，国际发售占90%。发售价 为每股4.51港元，净筹约4.95亿港元。H股预计于2025年12月19日上午九时起在联交所买卖。香港公开 发售获5248.15倍认购，国际发售获2.68倍认购。 ...

Group 1 - Two studies published in Nature confirm the efficacy and safety of a new diabetes drug, Masitide, developed by China's Innovent Biologics and Eli Lilly, showing superior blood sugar control and weight loss compared to placebo and Dulaglutide [1] - The studies involved Phase III clinical trials with Chinese type 2 diabetes patients, demonstrating improvements in cardiovascular, liver, and kidney-related indicators [1] - Masitide is a dual receptor agonist for glucagon-like peptide-1 and glucagon, providing high-quality evidence for overweight, obese, and diabetic patients, highlighting China's research capabilities in this field [1] Group 2 - U.S. stock indices rose collectively, with the Dow Jones up 65.88 points (0.14%), S&P 500 up 53.33 points (0.79%), and Nasdaq up 313.04 points (1.38%), driven by gains in large tech stocks [2] - Notable stock performances included Tesla rising over 3%, and Micron Technology increasing over 10% [2] - Chinese concept stocks also saw gains, with Zhihu up over 3% and XPeng Motors up over 2% [2] Group 3 - The State Council of China issued an opinion to combat illegal tobacco activities, focusing on countering counterfeit and smuggled tobacco products, and enhancing law enforcement collaboration with other countries [3] - The opinion aims to purify the tobacco market environment and protect national interests and consumer rights [3] Group 4 - BHP CEO Mike Henry emphasized the critical role of copper in the economy and its demand surge, predicting a bull market for copper due to supply constraints [4] - The annual market size for copper is estimated between $300 billion and $400 billion, with a projected 70% increase in demand by 2050, while new mining discoveries are becoming rarer and more challenging to develop [4] Group 5 - Meituan released and open-sourced a state-of-the-art virtual human video generation model, LongCat-Video-Avatar, which supports multiple tasks and has undergone significant upgrades in realism and stability [5] Group 6 - Zhihui Mining's shares rose 126.16% in dark trading, with a planned global offering of 122 million H-shares at HKD 4.51 each, focusing on zinc, lead, and copper mining in Tibet [6] Group 7 - Evergrande Auto announced a change in the registered shareholder of its subsidiary to Guangzhou Juliyi, with stock trading suspended pending further notice [7] Group 8 - Wasion Holdings' subsidiary won a contract worth over RMB 80 million for a project with CPFL, a leading power company in Brazil, and expects significant growth in AI data center revenues [8] - The company anticipates a doubling of AI data center revenue from RMB 1 billion in 2025 to RMB 2 billion in 2026, with new orders expected to grow significantly [8] Group 9 - Citigroup raised its profit forecasts for Wasion Holdings by 1% to 5% for 2025-2027, increasing the target price from HKD 15.5 to HKD 21, maintaining a "buy" rating [9]

New IPOs - The largest biotech IPO in Hong Kong for 2025 is initiated by Insilico Medicine (03696), which boasts the fastest global progress in AI drug development [1] - Lin Qingxuan (02657) will conduct its IPO from December 18 to December 23, attracting cornerstone investors like Fidelity [1] - Woan Robotics (06600) is set to launch its IPO during the same period, with an expected listing date of December 30 [1] - Meilian Holdings (02671) and Wuyi Vision (06651) will also hold their IPOs from December 18 to December 23, both expected to list on December 30 [1] - Xun Ce (03317) will follow the same IPO schedule, with a listing anticipated on December 30 [1] - Zhihui Mining (02546) achieved a remarkable 5248.15 times subscription in its public offering, with a listing date of December 19 [1] - China National Airlines (00753) plans to invest in Shenzhen Airlines' equity financing, with Kunhang Investment, a state-owned entity, being shortlisted [1] - Sensetime-W (00020) intends to place 1.75 billion new Class B shares, aiming to raise approximately HKD 3.146 billion [1] - Fosun Pharma (02196) is enhancing its overseas innovative drug strategy by signing a cooperation and option agreement with Clavis Bio [1] - WuXi AppTec (02359) invested around EUR 30 million to acquire a 3.22% stake in a French biopharmaceutical fund [1] - Minhua Holdings (01999) plans to acquire 100% equity in the American soft furniture company Gainline Recline Intermediate Corp [1] Share Buybacks - Tencent Holdings (00700) repurchased 1.055 million shares for HKD 636 million on December 18 [2] - Xiaomi Group-W (01810) spent HKD 151 million to buy back 3.75 million shares on the same day [2] - COSCO Shipping Holdings (01919) repurchased 5.9 million shares for HKD 80.557 million [2] - Country Garden Services (06098) bought back 2.7 million shares for HKD 17.136 million [2] - Jiangsu Ninghu Expressway (00177) saw an increase of 52.862 million shares by Yunsong Capital [2]

智汇矿业(02546)公布配发结果，公司全球发售1.22亿股H股，香港公开发售占10%，国际发售占90%。 每股发售价4.51港元，全球发售净筹约4.95亿港元。每手1000股，预期H股将于2025年12月19日(星期五) 上午九时正开始在联交所买卖。 其中，香港公开发售获5248.15倍认购，国际发售获2.68倍认购。 ...

智通财经APP讯，智汇矿业(02546)公布配发结果，公司全球发售1.22亿股H股，香港公开发售占10%， 国际发售占90%。每股发售价4.51港元，全球发售净筹约4.95亿港元。每手1000股，预期H股将于2025 年12月19日(星期五)上午九时正开始在联交所买卖。 其中，香港公开发售获5248.15倍认购，国际发售获2.68倍认购。 ...